Jens Ulrich

Jens Ulrich

Quedlinburg, ST, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 74 publications

Treatment patterns in geriatric patients with melanoma and the effect of age on the efficacy of immunotherapy: Analysis from the real-world multicenter registry ADOREG.

Treatment patterns in geriatric patients with melanoma and the effect of age on the efficacy of immunotherapy: Analysis from the real-world multicenter registry ADOREG.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 16, 2026

COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant Melanoma.

COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant Melanoma.

Journal: Cancers

Published: January 13, 2026

Enhanced overall and progression-free survival in advanced melanoma patients undergoing targeted therapy alongside antithrombotic treatment - Insights from a multicenter study involving 1296 patients from the prospective skin cancer registry ADOReg.

Enhanced overall and progression-free survival in advanced melanoma patients undergoing targeted therapy alongside antithrombotic treatment - Insights from a multicenter study involving 1296 patients from the prospective skin cancer registry ADOReg.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 12, 2025

Real-world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO study.

Real-world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO study.

Journal: International journal of cancer

Published: May 23, 2025

Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma.

Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 24, 2025

First-line checkpoint inhibitor therapy in metastatic acral lentiginous melanoma compared to other types of cutaneous melanoma: A multicenter study from the prospective skin cancer registry ADOREG.

First-line checkpoint inhibitor therapy in metastatic acral lentiginous melanoma compared to other types of cutaneous melanoma: A multicenter study from the prospective skin cancer registry ADOREG.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 24, 2025

Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanoma.

Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanoma.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: October 30, 2024

Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy - A multicenter study on 2419 patients from the prospective skin cancer registry ADOReg.

Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy - A multicenter study on 2419 patients from the prospective skin cancer registry ADOReg.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 13, 2024

Treatment at the end of life in patients with advanced melanoma. A multicenter DeCOG study of 1067 patients from the prospective skin cancer registry ADOReg.

Treatment at the end of life in patients with advanced melanoma. A multicenter DeCOG study of 1067 patients from the prospective skin cancer registry ADOReg.

Journal: Frontiers in immunology

Published: October 11, 2024

Early versus late response to PD-1-based immunotherapy in metastatic melanoma.

Early versus late response to PD-1-based immunotherapy in metastatic melanoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 05, 2024

Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomas.

Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomas.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 10, 2024

Influence of adjuvant therapies on organ-specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry ADOReg.

Influence of adjuvant therapies on organ-specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry ADOReg.

Journal: International journal of cancer

Published: March 08, 2024

Showing 1-12 of 74

Last Updated: 09/26/2026